NEW YORK (GenomeWeb News) – Horizon Discovery said today that Millenium Pharmaceuticals will evaluate seven of Horizon’s X-MAN normal and mutant isogenic cell lines during an eight-month period.
The X-MAN cell lines may help speed the discovery of personalized cancer medicine, the company said. These cell lines are genetically defined in vitro models of human cancer and their matched normal cell types. They include a set of double cancer-gene "knock-in" lines designed to evaluate patient resistance to targeted agents.
The lines Millenium is studying are model genotypes, and the drug developer will use them to characterize and test known targeted agents and internally developed compounds.
Horizon said Millenium will pay it a “six-figure fee and share key data sets during the course of the evaluation” beginning in October. Further terms of the agreement were not disclosed.